Feature

Opioid prescribing mapped: Alabama highest, New York lowest


 

Medicare beneficiaries in Alabama were more likely to get a prescription for an opioid than in any other state in 2019, based on newly released data.

Opioid prescribing rates for Medicare part D in 2019

That year, opioids represented 6.48% of all drug claims for part D enrollees in the state, just ahead of Utah at 6.41%. Idaho, at 6.07%, was the only other state with an opioid prescribing rate over 6%, while Oklahoma came in at an even 6.0%, according to the latest update of the Centers for Medicare & Medicaid Services’ dataset.

The lowest rate in 2019 belonged to New York, where 2.51% of drug claims, including original prescriptions and refills, involved an opioid. Rhode Island was next at 2.87%, followed by New Jersey (3.23%), Massachusetts (3.26%), and North Dakota (3.39%),

Altogether, Medicare part D processed 1.5 billion drug claims in 2019, of which 66.1 million, or 4.41%, involved opioids. Both of the opioid numbers were down from 2018, when opioids represented 4.68% (70.2 million) of the 1.5 billion total claims, and from 2014, when opioids were involved in 5.73% (81,026,831) of the 1.41 billion drug claims, the CMS data show. That works out to 5.77% fewer opioids in 2019, compared with 2014, despite the increase in total volume.

Among the states, Delaware had the largest 5-year decrease, 2.38 percentage points, as its opioid prescribing rate dropped from 6.61% to 4.23% from 2014 to 2019, with Hawaii showing the smallest decline as it slipped 0.41 percentage points from 3.9% to 3.49%, according to the CMS.

In 2019, part D beneficiaries in Vermont were the most likely to receive a long-acting opioid, which accounted for 20.14% of all opioid prescriptions in the state, while Kentucky had the lowest share of prescriptions written for long-acting forms at 6.41%. The national average was 11.02%, dropping from 11.79% in 2018 and 12.75% in 2014, the CMS reported.

Recommended Reading

Sen. Schumer backs federal decriminalization of marijuana
MDedge Psychiatry
Opioid prescribing laws having an impact
MDedge Psychiatry
EDs saw more benzodiazepine overdoses, but fewer patients overall, in 2020
MDedge Psychiatry
‘Deeper dive’ into opioid overdose deaths during COVID pandemic
MDedge Psychiatry
Growing proportion of cardiac arrests in U.S. considered opioid related
MDedge Psychiatry
Opioid overdoses tied to lasting cognitive impairment
MDedge Psychiatry
As opioid deaths climb, human trials begin for vaccine
MDedge Psychiatry
Guideline gives weak support to trying oral medical cannabis for chronic pain
MDedge Psychiatry
‘Alarming’ increase in fake pills laced with fentanyl, methamphetamine, DEA warns 
MDedge Psychiatry
FDA okays new oral CGRP antagonist for migraine prevention
MDedge Psychiatry